Retatrutide

Retatrutide is an experimental, once-weekly injectable drug (also known as LY3437943) designed for weight loss and type 2 diabetes management, currently in Phase 3 trials. It acts as a "triple agonist" (Triple G), targeting three hormone receptors—GLP-1, GIP, and glucagon—to suppress appetite, increase satiety, and boost energy expenditure.

• Mechanism of Action: While targeting GIP and GLP-1 slows digestion, the addition of glucagon stimulation helps speed up metabolism and fat burning.

• Metabolic Benefits: In addition to weight loss, studies indicate potential for significant reductions in liver fat and improvements in glucose control (HbA1c).

• LY3437943

• Retatrutide

• Reta

• There are no long-term human studies, and these peptides are not approved by the FDA, with potential risks unknown.

• They are often sourced through specialized, clinician-guided, or anti-aging, clinics.